HOUSTON, June 1, 2026 (Newswire.com) –
Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) (“Ainos” or the “Company”), a Smell AI company that digitizes scent into machine-readable data for artificial intelligence applications, today announced the deployment of AI Nose within a live emergency department environment for intelligent environmental monitoring, early warning of ER overcrowding, and respiratory infections at National Taiwan University Hospital (“NTUH”), one of Asia’s leading academic medical centers. announced the start of a research program to introduce Risk analysis.
The program aims to extend Smell AI, powered by AI Nose, within real-world emergency department environments and extend market opportunities beyond semiconductor and industrial environments to front-line medical infrastructure.
The study, titled “Application of AI electronic nose for intelligent environmental monitoring to establish an early warning system against emergency department overcrowding and respiratory infection risk,” will implement an AI nasal system throughout the waiting room, treatment area, and observation zone within the NTUH emergency department.
The system continuously analyzes environmental scent patterns and a wide range of environmental signals related to crowd density, patient flow, waiting conditions, and environmental changes related to respiratory infections.
Ainos has designed a project that goes beyond traditional volatile organic compound (“VOC”) monitoring to create an AI-powered environmental intelligence infrastructure for complex healthcare environments.
Ainos believes that emergency departments are some of the most challenging environments in which to operate in health systems around the world. The constant movement of patients, visitors, and medical staff results in continuous changes in airflow, occupancy, and environmental conditions, while overcrowding and the risk of respiratory infections remain major operational and public health challenges.
Ainos uses AI Nose to convert complex environmental odor and air pattern signals into machine-readable digital data called “Odor ID.” We use that data to develop healthcare-specific environmental mapping and AI-powered risk models.
This study will generate over 2,500 hours of emergency department environmental data and support the development of an AI model designed to analyze:
-
Emergency department crowding
-
Relationship between crowd density and environmental change
-
Environmental signals associated with respiratory infections
-
High-risk congestion pattern alerts
-
Potential scalability across broader hospital environments
“This project represents an important step toward an AI-powered environmental intelligence infrastructure,” said Eddie Tsai, Chairman, President and CEO of Inos.
“With our deployment in a semiconductor facility, AI Nose has learned how to recognize abnormal environmental changes within a highly sensitive and high-risk environment. Emergency departments represent another highly complex real-world operational environment.”
“The challenge is not to detect a single environmental signal. The challenge is to understand how risk patterns change in real time across the environment.”
“We believe hospitals of the future will have the ability to not only see and hear operational risks, but also detect changes in their environment related to those risks through Smell AI.”
Ainos recently expanded its AI Nose commercialization efforts across smart manufacturing environments, including advanced semiconductor manufacturing. Through these implementations, we have accumulated operational experience in real-time monitoring, anomaly recognition, and environmental analysis in complex industrial environments.
Inos believes that semiconductor factories and emergency departments share important characteristics: high-density, high-sensitivity environments that require continuous monitoring and rapid situational awareness.
This program marks the strategic expansion of AI Nose from industrial scent AI to healthcare scent AI and broader public environmental risk monitoring applications.
Ainos believes that Smell AI, powered by AI Nose, has the potential to become a key enabler across smart hospitals, public health systems, smart buildings, and future intelligent urban infrastructure.
This research does not involve diagnosing individual patients or collecting images, audio recordings, or personally identifiable information. The researchers designed this project as a non-invasive environmental AI monitoring study focused on environmental-level pattern analysis.
NTUH’s Institutional Review Board (“IRB”) approved this study. The study is scheduled to begin on June 1, 2026 and will continue for approximately six months.
About AI nose
AI Nose digitizes scent into Smell ID, an AI-driven scent intelligence. The full-stack electronic nose platform integrates a high-precision MEMS sensor array and proprietary AI algorithms and is designed to support ppb-level scent detection sensitivity depending on application conditions and deployment configuration. Smell ID transforms analog scent signals into structured, actionable data, and its proprietary scent language model (SLM) is designed to learn, classify, and contextualize complex scent patterns over time.
AI Nose is built on more than a decade of deep scent data and medical technology expertise and is designed to support continuous monitoring, predictive analytics, and real-time alerts across industrial and manufacturing environments. AI Nose is offered under the SmellTech-as-a-Service architecture and is intended to support continuous access to scent intelligence, analytics, and AI-driven insights through a subscription-based deployment model.
About Ainos Co., Ltd.
Ainos, Inc. (NASDAQ:AIMD) is a dual-platform AI and biotechnology company pioneering olfactory technology and immunotherapy. The company’s AI Nose platform and olfactory language model (SLM) digitizes scent into a machine-readable data format, Smell ID, to power intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®a low-dose oral interferon for rare, autoimmune, and infectious diseases. Inos, a fusion of “AI” and “Nose,” is redefining machine perception for the sensory age. If you would like to learn more please visit: https://www.Ainos.com. Follow Ainos on X, formerly known as Twitter (@AinosInc) and linkedin To stay up to date. Visit the media room https://ainos.suite.accessnewswire.com.
Forward-looking statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current assumptions and expectations about future events and trends that will or may affect our business, strategy, operations and financial performance, and actual results and other events may differ materially from those expressed or implied by such statements due to a number of risks and uncertainties. Forward-looking statements inherently involve risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated in the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses in the foreseeable future. Ability to increase profitability. our ability to obtain additional funding to continue product development; the ability to accurately predict future performance; our ability to advance current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize developed product candidates; our ability to obtain and maintain regulatory approval for our product candidates; delays in completing the development and commercialization of our current and future product candidates; the development and commercialization of additional products, including diagnostic test equipment; our ability to compete in the marketplace; compliance with applicable laws, regulations, tariffs and the factors described in the Risk Factors section of our filings with the Securities and Exchange Commission (SEC); Because forward-looking statements inherently involve risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise these statements, whether as a result of new information, future events or developments or otherwise, except to the extent required by applicable law.
contact address
Investor information
ir@ainos.com
sauce: Ainos Co., Ltd.
Source: Ainos Co., Ltd.
